For Immediate Release: Tuesday, December 17, 2019 (RALEIGH) Attorney General Josh Stein filed a brief in support of the Federal Trade Commission’s efforts to challenge a pay-for-delay agreement between brand-name-drug manufacturer Endo and its generic-drug competitor, Impax. This type of anticompetitive contract costs pharmaceutical customers more than $3.5 billion each year. “When pharmaceutical companies collude […]
